Treatment
Conditions
Keywords
lipoprotein glomerulopathy, treatment, immunoadsorption, apolipoprotein E
Brief summary
The purpose of this study is to assess the efficacy and safety of immunoadsorption in the treatment of lipoprotein glomerulopathy.
Detailed description
Lipoprotein glomerulopathy is characterized by nephritic syndrome glomerular protein thrombi and lipid abnormalities, particularly with an elevated level of plasma apoprotein E (apoE).There are no efficiency way to treat lipoprotein glomerulopathy. We firstly successfully treat 2 patients by protein A immunoadsorption with remarkable decreased urine protein and reduction of lipoprotein thrombi on repeated renal biopsy.
Interventions
PROCEDUREimmunoadsorption
immunoadsorption
Sponsors
Nanjing University School of Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. A new diagnosis of lipoprotein glomerulopathy proved by histology and serology 2. Age 15\ 60 years, sex free
Exclusion criteria
1. Serum creatinine \> 500 umol/l 2. Severe viral infection(HBV, HCV, CMV) within 3 months of first randomization or known HIV infection 3. Congenital or acquired immunodeficiency 4. Patients with severe infection or central nervous system symptoms 5. Immediately life-threatening organ manifestations (e.g. lung haemorrhage or massive gastro-intestinal bleeding, heart failure due to pericarditis or myocarditis, liver dysfunction measured on at least 2 separate occasion)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy of immunoadsorption in the treatment of lipoprotein glomerulopathy. | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| To assess the safety of immunoadsorption in the treatment of lipoprotein glomerulopathy. | 3 months |
Countries
China
Outcome results
None listed